SCHEMBL1335159

SCHEMBL1335159

COc1ccc(Br)c2c1C(=O)NC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.57
ALDH1A1 P00352 6/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 1/20 0.46
PIM1 P11309 1/20 0.45
CSNK1A1 P48729 1/20 0.45
CDK5 Q00535 1/20 0.45
ROCK1 Q13464 1/20 0.45
DYRK1A Q13627 1/20 0.45
LRRK2 Q5S007 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
NQO2 P16083 1/20 0.43
KDR P35968 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
ACHE P22303 1/20 0.39
CYP1A2 P05177 1/20 0.38
MAPT P10636 3/20 0.38
S1PR4 O95977 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12087085 0.84 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL17269693 0.77 PIM1 (0.49) KDM4EPIM1CSNK1A1CDK5ROCK1
SCHEMBL1335378 0.77 PIM1 (0.40) KDM4EHPGDPIM1CSNK1A1CDK5
SCHEMBL3590380 0.76 PKM (0.44) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL2731794 0.76 PIM1 (0.39) KDM4EHPGDPIM1CSNK1A1CDK5
SCHEMBL1335507 0.74 PIM1 (0.35) KDM4EPIM1CSNK1A1CDK5ROCK1
SCHEMBL23089152 0.74 PIM1 (0.49) KDM4EPIM1CSNK1A1CDK5ROCK1
SCHEMBL3041897 0.74 PIM1 (0.49) ALDH1A1PIM1CSNK1A1CDK5ROCK1
SCHEMBL22663398 0.74 PIM1 (0.49) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL1335445 0.74 PIM1 (0.49) PIM1CSNK1A1CDK5ROCK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119462608-A Fused ring CYP11A1 inhibitors 轩竹生物科技股份有限公司 2025-02-18 CN disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 US disclosed
WO-2021262684-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-12-30 WO disclosed
WO-2012061602-A1 ISOINDOLINONE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2012-05-10 WO disclosed
US-20110275630-A1 ISOINDOLINONE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2011-11-10 US disclosed
US-20100076051-A1 ISOINDOLINONE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-25 US disclosed
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2103620-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-09-23 EP disclosed
WO-2009051417-A2 PHENANTHRENE LACTAM DERIVATIVES HAVING ANTICANCER ACTIVITY AND METHOD FOR THE PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-04-23 WO disclosed
US-20060287370-A1 Isoindolinone kinase inhibitors CURTIN MICHAEL L 2006-12-21 US disclosed
US-7129260-B2 Isoindolinone kinase inhibitors ABBOTT LABORATORIES (US) 2006-10-31 US disclosed
EP-1633710-A1 ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS Abbott Laboratories (US) 2006-03-15 EP disclosed
US-20050026976-A1 Isoindolinone kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed
WO-2004108672-A1 ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287370-A1 Isoindolinone kinase inhibitors ABL1, LCK, MAP3K7 KDM4E 1054/4885ALDH1A1 2410/4885HPGD 1926/4885
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS KDM4E 3236/4885ALDH1A1 2214/4885HPGD 1279/4885
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND ERBB2, ROS1, FLT3 KDM4E 621/4885ALDH1A1 2591/4885HPGD 2243/4885
US-20050026976-A1 Isoindolinone kinase inhibitors ABL1, LCK, MAP3K7 KDM4E 1054/4885ALDH1A1 2410/4885HPGD 1926/4885
US-20100076051-A1 ISOINDOLINONE KINASE INHIBITORS ABL1, LCK, MAP3K7 KDM4E 1054/4885ALDH1A1 2410/4885HPGD 1926/4885
US-20110275630-A1 ISOINDOLINONE KINASE INHIBITORS MAP3K7, MAP3K5, MAP3K20 KDM4E 982/4885ALDH1A1 2721/4885HPGD 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.